Inserm Transfert, your partner for value creation and technology transfer

Inserm Transfert, founded in 2000, is the private subsidiary of Inserm, specialized in life sciences technology transfer and collaborative research projects funding. It works under a Public Service Concession Agreement (CSP).

0

patent families*

0

number of contracts and licenses*

* For the year 2023

0

millions of euros invested in Proof of concept

0

projects detected*

Serving research

The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological research to clinical development, with the aim of creating economic and societal value.

You are

News

M2care et Inserm Transfert annoncent la signature d’une alliance

Industrial Partnerships December 2024

Inserm Transfert participe au DEMO DAY 2024 #1 de PariSanté Campus le

Agenda November 2024

La contribution à la mise en place de la Cellule Europe Mutualisée

Industrial Partnerships October 2024

AndzonBio1 raises initial €3M in seed funding to advance

Entrepreneurship October 2024

Inserm Transfert partenaire de Deeptech Voit BIG le 9 octobre !

Agenda October 2024

Inserm Transfert et PULSALYS misent sur l'innovation et le collectif,

Institutional Partnerships September 2024

Lyonbiopôle - Armelle Sérose, Strategic Alliances Manager | AuRA

Event July 2024

Inserm Transfert and AdBio partners launch AndzonBio®

Entrepreneurship June 2024

Inserm Transfert participe au Congrès C.U.R.I.E. du 10 au 12 juin à

Agenda June 2024

Inserm Transfert partenaire de la 9ème journée du SNITEM le 4 juin !

Event June 2024

Inserm Transfert will be present at BIO International Convention from

Event June 2024

Evotec, Inserm, Lille University Hospital and Inserm Transfert enter

Industrial Partnerships May 2024

Le Canceropôle Provence-Alpes-Côte d’Azur et Inserm Transfert

Institutional Partnerships May 2024

La matinée du P.U.I Normandie le 29 mai

Agenda May 2024

Inserm Transfert, partenaire du Deep Tech Tour de Lille le 28 mai !

Event April 2024

Une valorisatrice à l'honneur - Pascale Augé - Présidente du

Event March 2024

Constances cohort and Quinten Health partner to develop

Industrial Partnerships February 2024

Inserm Transfert, partenaire du Deep Tech Tour Centre Val de Loire le

Event January 2024

DeepLife and Inserm Transfert sign a research collaboration involving

Industrial Partnerships January 2024

Inserm Transfert partenaire du Deeptech Tour de Lyon le 5 décembre !

Event December 2023

Inserm Transfert partenaire du Deeptech Tour de Nantes le 21 novembre

Event November 2023

Inserm Transfert partenaire du Deeptech Tour de Reims le 13 novembre !

Event November 2023

Inserm Transfert partenaire du Deeptech Tour à Grenoble le 17 octobre

Event October 2023

2e Rencontres Interdisciplinaires de l’Oncosphère les 16 et 17

Event October 2023

Inserm Transfert partenaire de la Deeptech voit BIG le 4 octobre !

Event September 2023

Une année 2022 marquée par la nouveauté et une dynamique collective

Inserm Transfert September 2023

Inserm Transfert partenaire du Deeptech Tour à Montpellier le 13

Event August 2023

Journée mondiale du Vitiligo : Almirall et Inserm Transfert se

Industrial Partnerships June 2023

Protéger et valoriser les résultats de recherche

Event June 2023

Inserm Transfert partner of the 11th Antibody Industrial Symposium

Event June 2023

MEDETIA, in partnership with Institut Imagine and Inserm Transfert,

Industrial Partnerships

Inserm Transfert participe au Congrès Curie du 12 au 14 juin à Reims

Event June 2023

Inserm Transfert et Sanofi : 2 partenariats au bénéfice de

Industrial Partnerships May 2023

Inserm Transfert est partenaire de la 8ème journée du SNITEM le 4

Event March 2023

« Vive l’entrepreneuriat au féminin »

Entrepreneurship March 2023

Le consortium CATRIEM, collectif de 24 membres de l'écosystème de

Institutional Partnerships February 2023

Les 2 consortia COMS@N et COMBio, collectifs de respectivement 24 et

Institutional Partnerships February 2023

Inovalo360, l’Ecole d’hiver annuelle en Innovation et Valorisation

Event January 2023

Inserm Transfert partenaire du Deeptech Tour Normandie le 16 novembre

Event November 2022

Inserm Transfert announces the signature of a collaboration agreement

Industrial Partnerships November 2022

Theranexus and Inserm Transfert sign a strategic alliance to identify

Industrial Partnerships October 2022

Projets collaboratifs Europe : les appels à projets Horizon Europe et

Event October 2022

Inserm Transfert partenaire de la Deeptech voit BIG le 5 octobre !

Event October 2022

POLYGON Therapeutics and Inserm Transfert sign a 18-month agreement

Entrepreneurship September 2022

Une année 2021 exceptionnelle : des résultats financiers soulignant

Inserm Transfert July 2022

10th Antibody Industrial Symposium AIS2022

Event June 2022

Inserm Transfert sera présent au Congrès Curie 2022

Event June 2022

Inserm Transfert partenaire du Deeptech Tour Paris Cité le 2 juin !

Event June 2022

Almirall and Inserm Transfert enter into a licensing and research

Industrial Partnerships May 2022

Inserm Transfert partenaire du Deeptech Rennes le 18 mai !

Event May 2022

PIK3CA-related overgrowth syndrome (PROS) Inserm Transfert announces

Industrial Partnerships May 2022

Inserm Transfert partner of the 7th edition of the Innovative Medical

Event May 2022

AdBio partners welcomes Inserm Transfert as investor in second fund

Entrepreneurship May 2022

Inserm Transfert partenaire du Deeptech Toulouse le 22 avril !

Event April 2022

Considérations éthiques et valorisation de la propriété

Event March 2022

Lys Therapeutics and Inserm Transfert sign a three-year agreement for

Industrial Partnerships March 2022

Linkinvax and Inserm Transfert enter into an exclusive worldwide

Industrial Partnerships February 2022

Inserm Transfert partenaire du Deeptech Aix Marseille le 4 février

Event January 2022

"Les Colles de la Valo"

Event January 2022

Matinée Valorisation Ecole Universitaire de Recherche « Chimie

Event January 2022

Inserm Transfert partenaire du Deeptech Tour Nice le 25 novembre

Event November 2021

Inserm Transfert participe à DeepTech Connect le 17 novembre pour

Inserm Transfert November 2021

Tandem Deeptech

Event October 2021

Lancement plateforme LesDeeptech.fr

Event September 2021

Activity report 2020

Event September 2021

Plus d’un milliard d’Euros de financements européens pour les

Collaborative projects September 2021

Inserm Transfert présente ses résultats 2020 marqués par le soutien

Inserm Transfert July 2021

9th Antibody Industrial Symposium (AIS2021)

Event June 2021

Congrès Curie - June 2021

Event June 2021

Tech Tour France Transfer Invest 2021

Event April 2021

Inserm Transfert takes part in BIO-Europe Spring

Event November 2020

Inserm Transfert partner of the 6th edition of the Innovative Medical

Event March 2021

AstraZeneca, l’Institut Carnot CALYM et Inserm Transfert pour

Industrial Partnerships February 2021

Une évaluation externe confirme le haut niveau de professionnalisme

Inserm Transfert December 2020

Le Canceropôle Provence-Alpes-Côte d’Azur et Inserm Transfert

Institutional Partnerships December 2020

Le consortium PBS, conduit par l'incubateur Paris Biotech Santé,

Institutional Partnerships December 2020

Inserm Transfert partenaire de la 8ème édition du congres #8AIS2020

Event November 2020

Launch of atlas : an ambitious collaborative public/private research

Industrial Partnerships September 2020

Inserm Transfert renforce sa gouvernance avec notamment l’arrivée

Inserm Transfert September 2020

Inserm Transfert présente ses résultats 2019 et confirme son

Inserm Transfert June 2020

Inserm Transfert accompagne 7 nouveaux projets européens de recherche

Collaborative projects March 2020

4ème édition du Tech Tour Transfer Invest (TTTI)

Entrepreneurship February 2020

5 start-up issues de la valorisation de la recherche de l’Inserm, et

Entrepreneurship February 2020

Inserm Transfert at BioFIT 2019, Booth n°H20: Create value and

Industrial Partnerships December 2019

Inserm Transfert et PULSALYS signent un accord de partenariat

Institutional Partnerships October 2019

Projets européens : les nouveaux succès remarquables de 2018

Collaborative projects September 2019

Inserm Transfert se félicite du Prix de l’inventeur européen

Intellectual Property July 2019

Therachon : un bel exemple de succès collectif pour une start-up,

Industrial Partnerships June 2019

Human Health Startup Factory (HHSF) le consortium porté par Inserm

Industrial Partnerships January 2019

Collaborative projects

High-quality support for a research excellence.

INVENTS

Horizon Europe

The evaluation of new medicines for rare diseases is challenging for several reasons, among which are the small patient sample sizes, heterogeneity of patients and diseases and heterogeneity in ...

HT-ADVANCE

Horizon Europe

HT-ADVANCE we aim to revolutionise personalised management of arterial hypertension (HT) by using multi-omics (MOMICS) stratification biomarkers as companion diagnostics for the prescription of ...

MPX-RESPONSE

Horizon Europe

The aims of the MPX-RESPONSE project were to enhance understanding of mpox (Monkeypox), evaluate potential treatments, and bolster Europe's preparedness for emerging infectious disease outbreaks. The ...

ARTIDe

Horizon Europe

ARTiDe aims to develop a new antigen-specific immunotherapy for type 1 diabetes, via genetic engineering, using patients' regulatory T lymphocytes (Treg) to express an autoreactive T lymphocyte ...

MITI2

Horizon Europe

Inflammatory bowel disease (IBD) refers to a group of chronic conditions that cause inflammation in the digestive tract. IBD requires long-term management and treatment, which includes medication, ...

OBELISK

Horizon Europe

The Obelisk project consists of developing tools for predicting obesity during the first 1,000 days of life and testing innovative prevention programs, particularly among adolescents, in several ...

BE READY

Horizon Europe

European partnership for pandemic preparedness The COVID-19 pandemic has taught us that planning and investing in research and innovation well before a health crisis occurs is crucial in predicting ...

ISIDORe

Horizon Europe

The ISIDORe project assembles the largest and most diverse research and service-providing instrument to study infectious diseases in Europe, with expertise from structural biology to clinical trials. ...

CARE-IN-HEALTH

Horizon Europe

Cardiovascular disease prevention through an immunological blueprint Epidemiological evidence suggests an association between chronic inflammation and risk for cardiovascular disease (CVD). ...

INTERCEPT-T2D

Horizon Europe

Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous ...

HERVCOV

Horizon Europe

The HERVCOV project aims to analyze the role of human endogenous retroviruses (HERVs), known for their high pro-inflammatory potential, in the immunopathogenesis of COVID-19 and its long-term ...

REGERNA

Horizon Europe

The main aim of the REGeRNA project is to develop a synthetic messenger RNA capable of reinducing cardiomyocyte proliferation in patients suffering from heart failure. Heart failure (HF) is a major ...

4.UNCAN.eu

Horizon Europe

The 15-month coordination and support action “4.UNCAN.eu” will generate a strategic agenda to launch UNCAN.eu, a European initiative to UNderstand CANcer proposed by the Mission Board and the ...

RITA-MI 2

H2020

RITA-MI 2 will conduct a phase 2b randomised double-blind placebo-controlled CT to assess the impact of B cell depletion with the CD20 mAb rituximab on left ventricular dysfunction and cardiac ...

CBIG-SCREEN

H2020

CBIG-SCREEN aims to tackle inequality in cervical cancer screening (CCS) continuum. Though CCS programmes drastically reduce cervical cancer mortality, they remain largely inaccessible and underused ...

EHVA

H2020

 the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. ...

EJP-RD

H2020

The European Joint Program on Rare Diseases brings over 130 institutions from 35 countries 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, ...

REMEDIA

H2020

The overall objective of the REMEDIA project is to determine how and to what extent the exposome affects the severity and morbidity of Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis ...

CARDIATEAM

IMI

Diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes. In many patients, the diabetes causes a type of heart dysfunction called cardiomyopathy, which is ...

ENSAT-HT

H2020

This project will develop and evaluate an omics-based stratified health promotion program for patients with endocrine forms of hypertension. ...

COSY

RHU

The aim of our project is to transform the outcome and the medical care of patients with overgrowth syndromes (OS) ...

EU-TRAIN

H2020

"End stage renal diseases affect more than 3,900,000 patients worldwide with approximately 6% growth rate in 2016. Kidney transplantation is currently the best therapeutic option with around 1,500,000...

KTD INNOV

RHU

KTD-Innov combines molecular medicine (MM) and health information technology (HIT) to deliver a precision immune monitoring and diagnosis system applied in kidney transplantation: the Integrative ...

HUGODECA

H2020

"The HUGODECA project is a European funded research initiative investigating how human gonads (either an ovary or a testis) develop in the embryo in order to understand how the initially bipotential ...

CARMMA

RHU

CARMMA is based on the hypothesis that obesity co-morbidities are associated with an early senescence of adipose tissue (AT). The main objective of CARMMA is to determine the common and central ...

iVASC

RHU

iVASC est un consortium de chercheurs, de cliniciens et d’industriels, qui vise à mettre au point de nouveaux outils de recherche dans le domaine de l’athérothrombose et à les appliquer à ...

CARE

IMI

The CARE consortium is a coalition of 37 academic institutions, pharmaceutical companies and non-profit research organizations whose main objectives are the development of therapeutics (i) to provide ...

TheraLymph

H2020

Lymphedema is a disabling condition of localised accumulation of fluid in a tissue caused by a compromised lymphatic system. It is an incurable disease that affects millions of people worldwide and is...

AB-DiRecT

IMI

Developing antibacterials for resistant infections. An alarming rise globally in antibiotic-resistant infections and a search for new solutions is the motivational force behind project AB-DiRecT. The ...

IP-CURE-B

H2020

To develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune ...

VHFMoDRAD

IMI

VHFMoDRAD will develop and deliver rapid and point-of-care singel/multiplex diagnostic tool(s) that will significantly increase our capacity to handle outbreaks with Filoviruses and other viral ...

CCHFVaccine

H2020

The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) ...

ERINHA-Advance

H2020

One of the great challenges of the 21st century is to develop the capacity to prevent and react to outbreaks caused by highly pathogenic human and animal microorganisms, which are generally ...

EU-JAV

EU health programme

EU-JAV brings together the European Commission, health ministries, international policymakers and organisations, institutes, universities from 20 countries and a wide range of stakeholders, including ...

ZIKAlliance

H2020

ZIKAlliance is a multinational, multi-disciplinary research consortium comprised of 54 partners worldwide. It investigates clinical, fundamental, environmental and social aspects of ZIKV infection, in...

EBOVAC2

IMI

" The main objective of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine....

R-LINK

H2020

The main objective of this study is to identify the eligibility criteria for treatment with lithium in bipolar I disorders (BDI) in terms of response, safety and tolerability. R-LiNK proposes a ...

QUID NASH

RHU

The main aim of the QUID-NASH program is to develop a virtual liver biopsy (non invasive) for the diagnosis and staging of NASH (Non Alcoholic SteatoHepatitis) in patients with type 2 diabetes,...

PREVAC-UP

EDCTP

The project PREVAC-UP is built around the PREVAC consortium. Its two primary objectives are to determine (i) the long-term immunogenicity and safety and (ii) durability of humoral and cellular immune ...

PREMSTEM

H2020

PREMSTEM aims to validate umbilical cord derived human mesenchymal stem cells as a regenerative therapy for encephalopathy of prematurity to improve the quality of life for preterm infants and reduce ...

OBERON

H2020

The OBERON project will build an integrated approach for testing and assessment (IATA) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery of ...

MIROCALS

H2020

Efficacy and safety of low-dose IL2 (ld-IL2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients...

miniNO

H2020

The miniNO project will conduct out pioneering research on the connection between alterations in minipuberty and infantile nitric oxide (NO) signaling in the brain, and comorbidities that appear later...

MEDIT-AGEING

H2020

As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all related...

MAD-CoV 2

IMI

The overall aim of MAD-CoV 2 project is to develop and deliver a treatment for COVID-19 patients, which will significantly increase our capacity to handle the current outbreak of SARS-CoV-2. In ...

JPsustaiND

H2020

The overall aim of JPsustaiND is to support the development and extension of the capacities of the EU Joint Programming Initiative on Neurodegenerative Diseases, in particular Alzheimer's (JPND). ...

JPcofuND2

H2020

With the objective of promoting research aimed at changing the trajectory of these debilitating diseases, JPco-fuND 2 launched in January 2019, a joint transnational call supported by 27 countries for...

JPco-fuND

H2020

With the objective of promoting research aimed at changing the trajectory of these debilitating diseases, JPco-fuND 2 launched in January 2019, a joint transnational call supported by 27 countries for...

HERA

H2020

HERA will set the priorities for an environment and health research agenda in the EU by adopting a holistic and systemic approach in the face of global environmental changes. Research will support ...

HBM4EU

H2020

HBM4EU is a joint effort of 30 countries, the European Environment Agency and the European Commission, co-funded under Horizon 2020. The initiative is coordinating and advancing human biomonitoring in...

FAIR-PARK-II

H2020

"FAIR PARK II will primarily investigate the effects of an iron chelation therapy on the progression of handicap in Parkinson's disease. The project will run for five years (2015 - 2020) and will see ...

FAIR

H2020

The project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome antimicrobial resistance in pneumonia. The research focuses on the unique immunomodulator flagellin that ...

EU-RESPONSE

H2020

The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and ...

EBRA

H2020

EBRA aims at reducing the fragmentation and duplication of research efforts and at fostering synergies through enhanced coordination of brain research efforts at the EU and global level....